8-K: Firefly Neuroscience Secures $7.4M ATM Offering, Amends CTO Bonus

Firefly Neuroscience, Inc. announced an At-the-Market offering for up to $7.4 million and revised its CTO's compensation structure, replacing an automatic bonus with a discretionary one.

Summary

• Firefly Neuroscience, Inc. (the Company) entered into an At-the-Market (ATM) Offering Agreement with Konik Capital Partners, LLC (the Sales Agent) on February 3, 2026.
• The ATM Agreement allows the Company to offer and sell shares of its common stock, par value $0.0001 per share, with an aggregate sales price of up to $7,434,266 through the Sales Agent.
• Sales will be conducted as an 'at the market offering' on The Nasdaq Stock Market LLC, with the Sales Agent using commercially reasonable efforts.
• The Company will pay the Sales Agent a commission equal to 2.0% of the aggregate gross proceeds from sales and will reimburse legal counsel fees up to $50,000 in aggregate, plus up to an additional $5,000 per due diligence update session (not exceeding $20,000 per fiscal year).
• Net proceeds from the ATM offering are intended for working capital and other general corporate purposes.
• On February 4, 2026, Firefly Neuroscience Ltd., a wholly-owned subsidiary, entered into an addendum to the employment agreement with Gil Issachar, the Company's Chief Technology Officer.
• The addendum amends Mr. Issachar's compensation, replacing his automatic annual bonus with eligibility for a discretionary annual bonus of up to one month of his gross salary, effective January 1, 2026.
• The discretionary bonus is a conditional payment and will not be considered part of the employee's salary for calculating social rights, including severance pay.
• Outstanding bonuses accrued for Mr. Issachar through December 31, 2025, totaling 157,500 NIS, will be paid in 24 equal monthly installments of 6,562.5 NIS each, subject to mandatory Israeli withholdings.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. The ATM offering provides financial flexibility and access to capital, which is beneficial, but it also introduces potential dilution. The executive compensation adjustment is a neutral to slightly positive governance move.

Positives

• The At-the-Market offering provides a flexible and efficient mechanism for raising capital up to $7,434,266, allowing the Company to access funds as needed without the immediate pricing pressure of a traditional offering.
• The proceeds from the ATM offering are designated for working capital and general corporate purposes, enhancing the Company's financial flexibility for ongoing operations and strategic initiatives.
• The amendment to the CTO's bonus structure shifts from an automatic payment to a discretionary one, potentially aligning compensation more closely with performance and company objectives.
• The structured payment plan for the 157,500 NIS in outstanding bonuses to the CTO resolves a past liability with clear terms over 24 months.

Negatives

• The ATM offering, if fully utilized, will result in dilution for existing shareholders as new shares are issued and sold.
• The 2.0% commission to the sales agent, along with legal and due diligence fees, will reduce the net proceeds available to the Company from the offering.
• The shift from an automatic to a discretionary bonus for the CTO could be perceived as a negative for the employee, potentially impacting morale or retention, although the filing does not provide this context.
• The payment of 157,500 NIS in outstanding bonuses, while structured, represents a cash outflow for the Company.

Risks

• The Company has no obligation to sell, and the Sales Agent is not obligated to buy or sell shares, meaning the Company may not be able to raise the full $7,434,266 or any amount if market conditions are unfavorable.
• Sales of shares 'at the market' could put downward pressure on the Company's stock price, especially if large volumes are sold over a short period.
• The issuance of new shares under the ATM Agreement will dilute the ownership interest of existing shareholders.
• The Company must continuously comply with SEC and Nasdaq listing requirements, and any failure could lead to suspension of trading or termination of the ATM Agreement.
• Changes to executive compensation, even if discretionary, could impact executive retention or motivation if not managed effectively.
• The Company agreed to provide indemnification and contribution to the Sales Agent against certain liabilities, including under the Securities Act, which could expose the Company to legal costs and damages.

Future Outlook

The Company intends to use the net proceeds from the At-the-Market offering for working capital and other general corporate purposes, providing flexibility for future operational and strategic needs. The ATM agreement allows for continuous equity sales, adapting to market conditions.

Management Comments

• The Company currently intends to use the net proceeds, after deducting the Sales Agent commission and the Company's offering expenses, that it receives upon the issuance and sale of Shares to or through the Sales Agent for working capital and other general corporate purposes.

Industry Context

StockSavvy.ai notes that At-the-Market (ATM) offerings are a common financing tool for publicly traded companies, particularly in sectors requiring flexible capital access like biotechnology or neuroscience, where R&D cycles can be long and unpredictable. This method allows companies to raise capital incrementally, minimizing immediate market impact compared to large, fixed-price offerings. The 2.0% commission rate is within typical industry ranges for such arrangements. The adjustment to executive compensation, while specific to Firefly, reflects a broader trend towards performance-based incentives and away from automatic payouts, aligning executive interests more closely with shareholder value.

Comparison to Industry Standards

• The 2.0% commission rate for the ATM offering is generally in line with industry standards for such agreements, which typically range from 1% to 3%. For example, similar ATM agreements by small-cap biotech companies like Cassava Sciences (SAVA) or Vaxart (VXRT) have featured comparable commission structures.
• The maximum aggregate sales price of $7,434,266 is relatively modest, suggesting a targeted capital raise rather than a large-scale financing round, which is common for companies seeking to manage dilution while funding specific operational needs.
• The shift to a discretionary bonus for the CTO aligns with best practices in corporate governance, emphasizing performance and board oversight in executive compensation, similar to practices seen in established tech and biotech firms like Moderna (MRNA) or BioNTech (BNTX), where executive bonuses are often tied to specific milestones or financial performance metrics.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from the ATM offering; increased financial flexibility for the company.
• Employees (specifically CTO): Shift from guaranteed to discretionary bonus, potentially impacting job security perception or motivation, but also a clear plan for past bonus payments.
• Creditors: Improved liquidity and financial stability from potential capital raise could be positive.

Next Steps

• The Company may, from time to time, offer and sell shares of its common stock through Konik Capital Partners, LLC under the ATM Agreement.
• Konik Capital Partners, LLC will use commercially reasonable efforts to sell shares based on instructions from the Company.
• The Company will disclose ATM sales in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
• The Company will continue to make monthly installment payments of 6,562.5 NIS to Gil Issachar for outstanding bonuses until the total of 157,500 NIS is paid.
• Gil Issachar will be eligible for a discretionary annual bonus up to one month of his gross salary, to be paid by March 1 of the relevant year.

Key Dates

Recommendation

The ATM offering provides a prudent and flexible capital-raising mechanism, which is a positive for the company's liquidity and operational runway. However, the potential for dilution exists, and the specific use of proceeds for 'general corporate purposes' lacks detailed strategic allocation. The executive compensation adjustment is a standard governance move. Given these factors, a 'hold' recommendation is appropriate as investors should monitor the actual utilization of the ATM facility and the company's strategic execution before making further investment decisions.

Keywords

Firefly Neuroscience, ATM Offering, At-the-Market, Equity Offering, Capital Raise, Common Stock, Nasdaq, SEC Filing, 8-K, Executive Compensation, CTO, Gil Issachar, Discretionary Bonus, Share Dilution, Corporate Finance, Securities Act, Konik Capital Partners